Transcripts Novartis AG Mexican S.E.

Actions

NVS N

US66987V1098

Produits pharmaceutiques

Cours en clôture Mexican S.E. Autres places de cotation 07/07/2026			Varia. 5j.	Varia. 1 janv.
2 742,00 ^MXN	+0,62 %		+0,62 %	+9,68 %

13/07	Novartis : Santé Canada approuve le Vanrafia pour le traitement de la néphropathie à IgA	MT
13/07	Le Canada homologue Vanrafia de Novartis	AW

Transcripts

28/04	Transcript : Novartis AG, Q1 2026 Earnings Call, Apr 28, 2026
06/03	Transcript : Novartis AG - Shareholder/Analyst Call
04/02	Transcript : Novartis AG, Q4 2025 Earnings Call, Feb 04, 2026
12/01	Transcript : Novartis AG Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 09:00 AM
01/12	Transcript : Novartis AG - Special Call
21/11	Transcript : Novartis AG - Shareholder/Analyst Call
20/11	Transcript : Novartis AG - Shareholder/Analyst Call
30/10/25	Transcript : Novartis AG - Special Call
28/10/25	Transcript : Novartis AG, Q3 2025 Earnings Call, Oct 28, 2025
17/07/25	Transcript : Novartis AG, Q2 2025 Earnings Call, Jul 17, 2025
29/04/25	Transcript : Novartis AG, Q1 2025 Earnings Call, Apr 29, 2025
31/01/25	Transcript : Novartis AG, Q4 2024 Earnings Call, Jan 31, 2025
14/01/25	Transcript : Novartis AG Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-14-2025 08:15 AM
09/12/24	Transcript : Novartis AG - Special Call
21/11/24	Transcript : Novartis AG - Shareholder/Analyst Call
29/10/24	Transcript : Novartis AG, Q3 2024 Earnings Call, Oct 29, 2024
28/10/24	Transcript : Novartis AG - Shareholder/Analyst Call
18/07/24	Transcript : Novartis AG, Q2 2024 Earnings Call, Jul 18, 2024
23/04/24	Transcript : Novartis AG, Q1 2024 Earnings Call, Apr 23, 2024
05/03/24	Transcript : Novartis AG - Shareholder/Analyst Call
06/02/24	Transcript : MorphoSys AG, Novartis AG - M&A Call
31/01/24	Transcript : Novartis AG, 2023 Earnings Call, Jan 31, 2024
08/01/24	Transcript : Novartis AG Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 08:15 AM
28/11/23	Transcript : Novartis AG - Special Call
13/11/23	Transcript : Novartis AG - Special Call